02.27.15
Research published in the Journal of Herbal Medicine demonstrated the positive effect of the antioxidant Emblica officinalis (Indian Goosebery, Phyllanthus emblica) on the cardiovascular, respiratory and antioxidant status of subjects with a history of smoking.
The randomized, double-blind, placebo controlled pilot study administered 250 mg of E. officinalis fruit extract (EOE) to 20 participants for twice a day for 60 days. A second group of 10 subjects received 250 mg of placebo twice a day for 60 days. The EOE was standardized to contain not less than 60% (w/w) of low molecular weight hydrolyzabletannoids (Emblicanin-A, Emblicanin-B, Pedunculagin, Punigluconin).
Subjective parameters including mouth hygiene, cough with expectoration, shortness of breath on exertion, loss of appetite, feelings of impending doom, palpitation, sleep deprivation, irritability, heart burn and tiredness were evaluated at 0 (baseline), 30 and 60 days. Objective parameters — hemogram, lipid profile, cardiovascular risk factors, genotoxicity, antioxidant status and pulmonary function were assessed at days 0 (baseline) and 60 of the study.
The EOE treated group showed a significant improvement compared to the placebo group in all the subjective and objective parameters tested with no reports of adverse events.
For more information: www.natreoninc.com
The randomized, double-blind, placebo controlled pilot study administered 250 mg of E. officinalis fruit extract (EOE) to 20 participants for twice a day for 60 days. A second group of 10 subjects received 250 mg of placebo twice a day for 60 days. The EOE was standardized to contain not less than 60% (w/w) of low molecular weight hydrolyzabletannoids (Emblicanin-A, Emblicanin-B, Pedunculagin, Punigluconin).
Subjective parameters including mouth hygiene, cough with expectoration, shortness of breath on exertion, loss of appetite, feelings of impending doom, palpitation, sleep deprivation, irritability, heart burn and tiredness were evaluated at 0 (baseline), 30 and 60 days. Objective parameters — hemogram, lipid profile, cardiovascular risk factors, genotoxicity, antioxidant status and pulmonary function were assessed at days 0 (baseline) and 60 of the study.
The EOE treated group showed a significant improvement compared to the placebo group in all the subjective and objective parameters tested with no reports of adverse events.
For more information: www.natreoninc.com
